[1]邱新文,周爱云,邱丘,等.非损伤阈值下微脉冲激光治疗慢性中心性浆液性脉络膜视网膜病变[J].眼科新进展,2020,40(11):1049-1054.[doi:10.13389/j.cnki.rao.2020.0235]
　QIU Xinwen,ZHOU Aiyun,QIU Qiu,et al.Non-invasive subthreshold micropulse laser in the treatment of chronic central serous chorioretinopathy[J].Recent Advances in Ophthalmology,2020,40(11):1049-1054.[doi:10.13389/j.cnki.rao.2020.0235]
点击复制

非损伤阈值下微脉冲激光治疗慢性中心性浆液性脉络膜视网膜病变/HTML
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
40卷
期数:
2020年11期
页码:
1049-1054
栏目:
应用研究
出版日期:
2020-11-05

文章信息/Info

Title:
Non-invasive subthreshold micropulse laser in the treatment of chronic central serous chorioretinopathy
作者:
邱新文; 周爱云; 邱丘; 任旋; 兰丽霞; 宋志杰; 叶波
330002　江西省南昌市，南昌爱尔眼科医院眼底病科
Author(s):
QIU Xinwen; ZHOU Aiyun; QIU Qiu; REN Xuan; LAN Lixia; SONG Zhijie; YE Bo
Department of Fundus Diseases,Nanchang Aier Eye Hospital，Nanchang 330002，Jiangxi Province，China
关键词:
中心性浆液性脉络膜视网膜病变; 阈值下微脉冲激光; 光动力疗法; 光学相干断层扫描血管成像; 自发荧光
Keywords:
central serous chorioretinopathy;  subthreshold micropulse laser;  photodynamic therapy;  optical coherence tomography angiography;  autofluorescence
分类号:
R774.5
DOI:
10.13389/j.cnki.rao.2020.0235
文献标志码:
A
摘要:
目的　探讨非损伤阈值下微脉冲激光(subthreshold micropulse laser,SML)治疗慢性中心性浆液性脉络膜视网膜病变(central serous chorioretinopathy,CSCR)的疗效与安全性。方法　前瞻性非随机病例对照研究。慢性CSCR患者60例(60眼)，分为3组：非治疗观察(non-therapeutic observation,NTO)组、光动力疗法(photodynamic therapy,PDT)组、SML组，每组20例(20眼)。通过光学相干断层扫描血管成像、自发荧光、黄斑完整评估仪等获取研究前后患眼的最佳矫正视力(best corrected visual acuity,BCVA)、视网膜敏感度(retinal sensitivity,RS)、视网膜下液(subretinal fluid,SRF)高度及消失时间、中心黄斑厚度(central macular thickness,CMT)、黄斑中心凹下脉络膜厚度(subfoveal choroidal thickness,SFCT)、脉络膜毛细血管血流面积(choriocapillaris flow area,CFA)等数据以及评估椭圆体带、视网膜色素上皮(retinal pigment epithelium,RPE)等损伤。结果　NTO组仅4眼SRF消失，消失时间为(2.98±0.34)个月；PDT组患眼经(1.25±0.44)次PDT治疗后SRF均消失，消失时间为(1.87±1.32)个月；SML组患眼经(2.70±1.63)次治疗后SRF均消失，消失时间为(3.50±2.06)个月，PDT组与SML组治疗次数及SRF消失时间相比差异均有统计学意义（均为P<0.05)。末次随访时，NTO组BCVA、RS稍改善，CMT、SCFT及CFA均较入组时下降，但末次随访时NTO组上述指标与PDT组、SML组比较差异均有统计学意义(均为P<0.05)；PDT组、SML组BCVA、RS及CFA均较治疗前明显改善,CMT与SCFT均较治疗前下降，两治疗组间各指标比较差异均无统计学意义 (均为P>0.05)。NTO组持续存在椭圆体带损伤，PDT组、SML组椭圆体带形态均改善，自发荧光均未见明显变化，均未见脉络膜新生血管，SML组未见滴定激光斑点。结论　慢性CSCR积极治疗可以避免黄斑结构与功能进一步损伤；SML治疗与PDT治疗结果类似,均能有效改善慢性CSCR患眼视功能与恢复视网膜形态结构，但SML治疗次数相对较多、恢复时间相对较长。
Abstract:
Objective　To evaluate the efficacy and safety of noninvasive subthreshold micropulse laser (SML) in the treatment of chronic central serous chorioretinopathy (CSCR).Methods　A prospective non-randomized case-control study was carried on 60 patients (60 eyes) with chronic CSCR were divided into three groups: non-therapeutic observation (NTO) group, photodynamic therapy (PDT) group and SML group with 20 cases in each group. Several data including best corrected visual acuity (BCVA), retinal sensitivity (RS), subretinal fluid (SRF) height and absorption time, central macular retinal thickness (CMT), subfoveal choroidal thickness (SFCT) and choriocapillaris flow area (CFA) were obtained before and after the study by optical coherence tomography angiography, autofluorescence and macular analyzer integrity assessment and evaluate the damage of ellipsoid zone (EZ) and retinal pigment epithelium (RPE).Results　Only 4 patients in the NTO group had SRF disappeared for (2.98±0.34) months, and all patients in the PDT group had SRF disappeared for (1.87±1.32) months after (1.25±0.44) times of PDT treatment. After treatment for (2.70±1.63) times, SRF disappeared for (3.50±2.06) months in the SML group. There were statistically significant differences in the number of treatments and the disappearance time of SRF between the PDT group and the SML group (both P<0.05). At the last follow-up, BCVA and RS were slightly improved, CMT, SCFT and CFA were not significantly decreased in NTO group compared with those before treatment, and there were significant differences between NTO group and PDT group and SML group (all P<0.05). BCVA, RS and CFA were significantly increased in PDT group and SML group, while CMT and SCFT were significantly decreased, and there were no statistically significant differences in the indicators between the two treatment groups (all P>0.05). EZ injury was persistent in NTO group. In PDT group and SML group, EZ morphology improved and recovered, AF showed no obvious change, and no choroidal neovascularization was observed. No RPE laser damage spots were found in SML group.Conclusion　Active treatment of chronic CSCR can avoid further damage of macular structure and function. SML treatment and PDT treatment ultimately have the same effect and can improve visual function and restore retinal morphological structure. It is safe and non-invasive, and the cost is low. However, SML treatment times increase and the recovery time is longer.

参考文献/References:

［1］　DARUICH A,MATET A,DIRANI A,BOUSQUET E,ZHAO M,FARMAN N,et al.Central serous chorioretinopathy:Recent findings and new physiopathology hypothesis［J］.Prog Retin Eye Res,2015,48:82-118.
［2］　YANNUZZI L A,SLAKTER J S,GROSS N E,SPAIDE R F,COSTA D L,HUANG S J,et al.Indocyanine green angiography-guided photodynamic therapy for treatment of chronic central serous chorioretinopathy:A pilot study［J］.Retina,2003,23(1):288-298.
［3］　KARIM S P,ADELMAN R A.Profile of verteporfin and its potential for the treatment of central serous chorioretinopathy［J］.Clin Ophthalmol，2013,7:1867-1875.
［4］　INAGAKI K,HAMADA M,OHKOSHI K.Minimally invasive laser treatment combined with intravitreal injection of anti-vascular endothelial growth factor for diabetic macular oedema［J］.Sci Rep,2019,9（1）:7585.
［5］　ABD ELHAMID A H.Subthreshold micropulse yellow laser treatment for nonresolving central serous chorioretinopathy［J］.Clin Ophthalmol,2015,9:2277-2283.
［6］　SCHOLZ P,ALTAY L,FAUSER S.A Review of subthreshold micropulse laser for treatment of macular disorders［J］.Adv Ther,2017,34:1528-1555.
［7］　WOOD E H,KARTH P A,SANISLO S R,MOSHFEGHI D M,PALANKER D V.Nondamaging retinal laser therapy for treatment of central serous chorioretino-pathy:What is the Evidence?［J］.Retina,2017,37(6):1021-1033.
［8］　GAWECKI M.Micropulse laser treatment of retinal diseases［J］.J Clin Med,2019,8（2）:242.
［9］　邱新文,任旋,兰丽霞,邱丘,叶波.光学相干断层扫描血管成像引导光动力疗法治疗慢性中心性浆液性脉络膜视网膜病变［J］.眼科新进展,2019,39(8):767-771.
QIU X W,REN X,LAN L X,QIU Q,YE B.Photodynamic therapy guided by optical coherence tomography angiography for treatment of chronic central serous chorioretinopathy［J］.Rec Adv Ophthalmol,2019,39(8):767-771.
［10］　ARORA S,SRIDHARAN P,ARORA T,CHHABRA M,GHOSH B.Subthreshold diode micropulse laser versus observation in acute central serous chorioretinopathy［J］.Clin Exp Optom,2019,102(1):79-85.
［11］　HAMOUD A,YOUNIS S.Subthreshold micropulse yellow laser treatment for central serous chorioretinopathy［J］.Int J Ophthalmic Pathol,2018,7(1):3.
［12］　SCHOLZ P,ERSOY L,BOON C,FAUSER S.Subthreshold micropulse laser (577 nm) treatment in chronic central serous chorioretinopathy［J］.Ophthalmologica,2015,234(2):189-194.
［13］　KIM Y J，KIM S Y，HA S，MOON D，SEONG S，KWON O W，et al.Short-duration multiple-session subthreshold micropulse yellow laser (577 nm) for chronic central serous chorioretinopathy:Results at 3 years［J］.Eye,2019,33(7):819-825.
［14］　SCHOLZ P,ALTAY L,FAUSER S.Comparison of subthreshold micropulse laser(577 nm) treatment and half-dose photodynamic therapy in patients with chronic central serous chorioretinopathy［J］.Eye,2016,30(11):1371-1377.

相似文献/References:

[1]刘卫华 杨新怀 黄勤 聂鑫 覃旭方 全婵娟.OCT与FFA在中心性浆液性脉络膜视网膜病变检查中的应用比较[J].眼科新进展,2013,33(9):000.
[2]张鹏 王雨生 胡丹 王海燕 张自峰.561nm 激光光凝治疗中心性浆液性脉络膜视网膜病变[J].眼科新进展,2013,33(3):000.
[3]童桂芳 周琼.中心性浆液性脉络膜视网膜病变的研究进展[J].眼科新进展,2013,33(3):000.
[4]唐风雷 朱珊梅 周建强 于忠兴 朱太春 谢秀雯 蒋星 陆人杰.中心性浆液性脉络膜视网膜病变的临床研究与治疗评价[J].眼科新进展,2013,33(11):000.
[5]王志立 李晓华 李士清 董应丽 李萍. 慢性迁延性中心性浆液性脉络膜视网膜病变的两种自发荧光特征[J].眼科新进展,2014,34(2):151.
[6]徐建锋 叶瑞珍 李贵洲 蔡泽煌. 低能量TTT治疗中心凹下渗漏型CSC的临床研究[J].眼科新进展,2014,34(3):239.
[7]黄丽华,陈素芳,邵毅,等. 非诺贝特治疗中心性浆液性脉络膜视网膜病变的临床研究[J].眼科新进展,2014,34(4):333.[doi:10.13389/j.cnki.rao.2014.0090]
[8]林杜生,张贵华,陈浩宇,等. 频域OCT在急性Vogt-小柳原田病和急性中心性浆液性脉络膜视网膜病变鉴别诊断中的应用[J].眼科新进展,2015,35(6):557.[doi:10.13389/j.cnki.rao.2015.0151]
　LIN Du-Sheng,ZHANG Gui-Hua,CHEN Hao-Yu,et al. Distinguishing acute Vogt-Koyanagi-Harada disease from acute central serous chorioretinopathy with spectral domain OCT[J].Recent Advances in Ophthalmology,2015,35(11):557.[doi:10.13389/j.cnki.rao.2015.0151]
[9]童桂芳,周琼,邵毅. 急性中心性浆液性脉络膜视网膜病变FFA与频域OCT图像对比研究[J].眼科新进展,2015,35(8):735.[doi:10.13389/j.cnki.rao.2015.0201]
　TONG Gui-Fang,ZHOU Qiong,SHAO Yi. A comparative study on image of FFA and FD-OCT in acute central serous chorioretinopathy[J].Recent Advances in Ophthalmology,2015,35(11):735.[doi:10.13389/j.cnki.rao.2015.0201]
[10]游慧,张学东.激光治疗中心性浆液性脉络膜视网膜病变的新进展[J].眼科新进展,2016,36(3):297.[doi:10.13389/j.cnki.rao.2016.0081]
　YOU Hui,ZHANG Xue-Dong.Recent advances in laser for central serous chorioretinopathy[J].Recent Advances in Ophthalmology,2016,36(11):297.[doi:10.13389/j.cnki.rao.2016.0081]

备注/Memo

备注/Memo:
江西省卫生健康委科技计划项目（编号:20202029）
更新日期/Last Update: 2020-11-05